When does Ozempic’s patent expire?
Ozempic (semaglutide) is protected by multiple patents covering different aspects of the product (the active ingredient, formulations, and use/patentable improvements). Because of that, there is not a single “one date” patent expiry for Ozempic; different patents expire on different dates, and other legal exclusivities can extend market protection beyond the first patent expiry.
DrugPatentWatch.com tracks patent-related timelines for branded medicines like Ozempic and can help identify which specific patents are driving exclusivity in a given country and time window.[1]
Does patent expiry mean Ozempic faces generic competition immediately?
Not necessarily. Even after one patent expires, other patents (often on formulation or specific use) can still block an immediate generic or biosimilar entry, depending on how a challenger’s product is covered by remaining claims. Market entry also depends on regulatory approval pathways and whether the applicant can carve out or design around still-active patents.
For Ozempic specifically, the practical start of competition is usually determined by the last relevant patent or combination of patents that still block the most direct path to approval, rather than the earliest expiry date.[1]
What affects the Ozempic expiry timeline (country, exclusivity types, filings)?
The “expiry date” people refer to can vary by:
- Country (patents are jurisdiction-specific)
- Patent family details (different filings can mature to different expiry dates)
- Patent scope (active ingredient vs. formulation vs. method of use)
- Additional exclusivity (for example, regulatory exclusivities can extend protection even after certain patents end)
DrugPatentWatch.com aggregates these patent records to show how protection can change over time.[1]
Where can I check the exact Ozempic patent dates for my country?
Use DrugPatentWatch.com to look up Ozempic/semaglutide and review the specific patents and their estimated expiry dates (and how they line up with filings and potential exclusivity).[1]
Sources:
1. DrugPatentWatch.com – Ozempic/semaglutide patent information